Yael Klionsky, MD
Rheumatology · Anchorage, AKNPI 1437506672
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AstraZeneca at 31.1% of the total. 2025 is the largest year on record at $49,845, more than ten times the $99 reported in 2021.
Across 258 payments — averaging $449.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36K
- Johnson & Johnson$34K
- AbbVie$16K
- Amgen$15K
- GSK$7K
- Eli Lilly$6K
- plus $2K from 12 others
Across 17 payments — averaging $6029.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$95K
- Amgen$7K
What the payments were for
- Consulting fees$29,09725%
- Speaking & faculty fees$65,24256%
- Travel & lodging$13,07011%
- Food & beverage$8,4737%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $36,054 |
| Johnson & Johnson | 59 | $34,408 |
| AbbVie | 31 | $16,011 |
| Amgen(2 entities) | 58 | $14,873 |
| GSK | 11 | $6,707 |
| Eli Lilly | 7 | $6,290 |
| Novartis | 8 | $357 |
| Pfizer | 6 | $338 |
| Lilly USA, LLC | 8 | $279 |
| Sanofi | 2 | $261 |
| UCB, Inc. | 4 | $121 |
| E.r. Squibb & Sons, L.L.C. | 5 | $103 |
| Aurinia Pharma U.S., Inc. | 3 | $65 |
| Genentech USA, Inc. | 2 | $44 |
| Radius Health, Inc. | 2 | $34 |
| Sobi, Inc | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few rheumatology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 103 | $835,413 |
| Enbrel SureclickEtanercept | 20 | $142,963 |
| Actemra ActpenTocilizumab | 27 | $127,647 |
| ForteoTeriparatide | 14 | $60,369 |
| MethotrexateMethotrexate Sodium | 163 | $3,216 |
| Hydroxychloroquine Sulfate | 66 | $2,354 |
| Leflunomide | 19 | $1,549 |
| Pilocarpine Hcl | 21 | $1,409 |
| Azathioprine | 13 | $965 |
| Prednisone | 105 | $861 |
| Colchicine | 15 | $685 |
| Sulfasalazine | 16 | $409 |
| Allopurinol | 24 | $392 |
| Folic Acid | 28 | $257 |
| Alendronate Sodium | 30 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $279 | $60,36914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other rheumatology in Anchorage
- John BotsonAnchorage$2.2M
- Cristina CopusAnchorage$3K
- Summer Engler JagerAnchorage$3K
- Ryan RagleAnchorage$3K
- Claribel TanAnchorage$713
- Javaneh LyonsAnchorage$102
- James HaigneyAnchorage$78
- Vivek MehtaAnchorage$33
- Elizabeth FerucciAnchorage$0
- Raymond WilsonFairbanks$274
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.